Stocks · News reference
Top 3 Health Care Stocks That May Rocket Higher In July
Health care sector oversold - buying opportunities in undervalued companies. RSI compares stock strength on up/down days, below 30 is oversold.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Opus Genetics, Inc. (IRD)
Filed: 2026-09-11 AccNo: 0001140361-26-036277 Size: 7 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Wedbush Maintains Outperform on Opus Genetics, Raises Price Target to $13
Wedbush analyst Yun Zhong maintains Opus Genetics (NASDAQ:IRD) with a Outperform and raises the price target from $10 to $13.
Oppenheimer Maintains Outperform on Opus Genetics, Raises Price Target to $20
Oppenheimer analyst Andreas Argyrides maintains Opus Genetics (NASDAQ:IRD) with a Outperform and raises the price target from $10 to $20.
HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $65 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Legend Biotech (NASDAQ:LEGN) with a Buy and maintains $65 price target.
Legend Biotech Reports 50% Of CARTITUDE-2 Patients Remained Progression-Free At 5 Years After Single CARVYKTI Infusion
Five-year overall survival rate was 69.2%, adding to growing long-term evidence supporting the curative potential of CARVYKTI in earlier-line RRMMBRIDGEWATER, N.J., Sept. 25, 2026 (GLOBE NEWSWIRE) -- Legend Biotech